Ftse Mib
34.374,77
0,55%
DAX
20.024,66
0,58%
S&P 500
5.868,55
-0,22%
NASDAQ
19.280,79
-0,16%
Bitcoin
96.998,90
0,11%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ United Therapeutics Corporation (UTHR) United Therapeutics Corporation (UTHR) Notizie

UTHR

United Therapeutics (UTHR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:UTHR
DataOraFonteTitoloSimboloCompagnia
31/12/202422:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
30/12/202422:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
17/12/202413:00Business WireUnited Therapeutics Announces Successful World’s First UKidney TransplantNASDAQ:UTHRUnited Therapeutics Corporation
08/11/202422:30Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:UTHRUnited Therapeutics Corporation
05/11/202422:30Business WireUnited Therapeutics Corporation to Present at the UBS Global Healthcare ConferenceNASDAQ:UTHRUnited Therapeutics Corporation
30/10/202411:34Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:UTHRUnited Therapeutics Corporation
30/10/202411:32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:UTHRUnited Therapeutics Corporation
30/10/202411:30Business WireUnited Therapeutics Corporation Reports Third Quarter 2024 Financial ResultsNASDAQ:UTHRUnited Therapeutics Corporation
23/10/202413:00Business WireUnited Therapeutics Corporation Announces the 500th Lung Transplant Utilizing its Centralized Ex Vivo Lung Perfusion ServiceNASDAQ:UTHRUnited Therapeutics Corporation
23/10/202412:30Business WireUnited Therapeutics Corporation to Report Third Quarter 2024 Financial Results Before the Market Opens on Wednesday, October 30, 2024NASDAQ:UTHRUnited Therapeutics Corporation
24/09/202413:00Business WireUnited Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the CHEST 2024 Annual MeetingNASDAQ:UTHRUnited Therapeutics Corporation
10/09/202413:00Business WireUnited Therapeutics Publishes its 2024 Corporate Responsibility and Public Benefit Report Highlighting its Progress Toward a Future Where No Patient Gets Left Behind—EverNASDAQ:UTHRUnited Therapeutics Corporation
28/08/202413:00Business WireUnited Therapeutics Corporation to Present at Upcoming Investor ConferencesNASDAQ:UTHRUnited Therapeutics Corporation
01/08/202416:54Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:UTHRUnited Therapeutics Corporation
31/07/202412:30Business WireUnited Therapeutics Corporation Reports Second Quarter 2024 Financial ResultsNASDAQ:UTHRUnited Therapeutics Corporation
24/07/202413:00Business WireUnited Therapeutics Corporation to Report Second Quarter 2024 Financial Results Before the Market Opens on Wednesday, July 31, 2024NASDAQ:UTHRUnited Therapeutics Corporation
10/07/202413:00Business WireUnited Therapeutics Corporation Announces Full Enrollment of the TETON 2 Study of Inhaled Treprostinil for the Treatment of Idiopathic Pulmonary FibrosisNASDAQ:UTHRUnited Therapeutics Corporation
27/06/202413:00Business WireUnited Therapeutics Corporation Announces Election of Jan Malcolm to its Board of DirectorsNASDAQ:UTHRUnited Therapeutics Corporation
05/06/202413:00Business WireUnited Therapeutics Corporation to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:UTHRUnited Therapeutics Corporation
31/05/202413:00Edgar (US Regulatory)Form SD - Specialized disclosure reportNASDAQ:UTHRUnited Therapeutics Corporation
01/05/202412:30Business WireUnited Therapeutics Corporation Reports First Quarter 2024 Financial ResultsNASDAQ:UTHRUnited Therapeutics Corporation
26/04/202420:02Business WireCORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney TransplantNASDAQ:UTHRUnited Therapeutics Corporation
24/04/202415:00Business WireUnited Therapeutics Announces World’s First Successful Xenothymokidney TransplantNASDAQ:UTHRUnited Therapeutics Corporation
24/04/202413:00Business WireUnited Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024NASDAQ:UTHRUnited Therapeutics Corporation
16/04/202413:00Business WireUnited Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International ConferenceNASDAQ:UTHRUnited Therapeutics Corporation
26/03/202412:00Business WireUnited Therapeutics Announces the First Comprehensive Review Publication on XenotransplantationNASDAQ:UTHRUnited Therapeutics Corporation
25/03/202412:00Business WireUnited Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase ProgramNASDAQ:UTHRUnited Therapeutics Corporation
05/03/202412:00Business WireUnited Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024NASDAQ:UTHRUnited Therapeutics Corporation
27/02/202412:00Business WireUnited Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:UTHRUnited Therapeutics Corporation
21/02/202412:03Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:UTHRUnited Therapeutics Corporation
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:UTHR

La tua Cronologia

COIN
AG10BTC
Agri10x Token
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network